Use capnography as a primary assessment tool for asthma and COPD exacerbation

Quantitative waveform capnography can help EMS providers recognize bronchospasm, spot ventilation derangements, and gauge the effectiveness of therapy

By Kelly Grayson

Obstructive airway disease is a constellation of chronic respiratory illnesses characterized by obstructed airflow through the terminal bronchioles and alveoli, either due to inflammation, obstruction by mucous and secretions, or loss of surface area for gas exchange from atelectasis. Asthma, bronchiectasis, emphysema, chronic bronchitis and cystic fibrosis all fall within the obstructive lung disease spectrum.

Of these, asthma is the most common chronic disease among children, and asthma affects nearly 235 million people of all ages worldwide [1]. In the U.S., roughly 25.5 million children and adults suffer from asthma, 9.8 percent and 8.0 percent of the population, respectively [2, 3].

In 2011, asthma resulted in 1.8 million emergency department visits, and was the primary diagnosis in 25 percent of pediatric emergency department visits [4].

Despite advances in treatment and disease recognition decreasing mortality rates in recent years, and the fact that 50 percent of young children with an asthma diagnosis will no longer experience symptoms after they reach adolescence, the prevalence of asthma continues to grow, increasing from roughly 20 million (7 percent) in 2001 to 25 million (8 percent) in 2009.

The surge in asthma diagnoses was starkest among black children, who experienced an increase in prevalence of nearly 50 percent from 2001 to 2009 [5].

The economic burden of asthma is significant, costing every diagnosed patient an average of $3,300 a year. The cost of asthma care in the United States rose 6 percent between 2001 and 2009, from $53 billion to $56 billion annually [5].

Understanding asthma
Asthma is a lower airway disease whose primary symptoms are dyspnea, wheezing and chest tightness, resulting from narrowing and spasm of the terminal bronchioles. The inflammation and excess mucous production prevalent in asthma exacerbation results from the release of cytokines and other inflammatory mediators. These cytokines, released from eosinophils, which are disease fighting white blood cells, are not present in the respiratory tract in significant numbers in non-asthma patients. Cytokines directly stimulate inflammation of bronchial smooth muscle and production of mucous from goblet cells, as well as trigger the activation of yet more eosinophils. The outcome is a hyper-reactive airway that results in acute bronchospasm when exposed to one of the many asthma triggers.

In acute bronchospasm, air becomes trapped in the terminal bronchioles and alveoli after gas exchange, resulting in an increase in functional dead space. This trapped air must be forcefully exhaled — normally the passive phase of the respiratory cycle — resulting in the characteristic expiratory wheeze of asthma exacerbation, as well as markedly increased work of breathing. Some asthma patients, particularly children, present with forceful, persistent coughing, another form of forced exhalation, rather than wheezing. As the airway lumen narrows further and mucous plugging occurs, flow is further restricted, resulting in inspiratory wheezing, and in severe cases, silent asthma.

Asthma assessment and treatment
The primary goal in EMS treatment of asthma is to reverse bronchospasm with Beta-2 agonist and parasympatholytic bronchodilators, with a secondary goal of reducing inflammation, typically with corticosteroids.

Assessment of acute bronchospasm in the field, however, is often complicated by the austere nature of the EMS work environment. High ambient noise, distractions from agitated family and bystanders, anxious and hypoxic patients unable to provide a complete history, and lack of access to more sophisticated testing methods can make the process quite challenging. While it may be fairly straightforward to recognize the presence of acute bronchospasm, quantifying the severity of it — and modifying treatment accordingly — can often be difficult.

In the hospital, two indices are used to gauge the severity of an asthma attack: spirometry and measurement of arterial blood gases (ABG). Each of these methods can be quite useful, but they also have their limitations.

Spirometry is a measure of expiratory airflow that can quantify Forced Vital Capacity (FVC), the amount of air you can exhale, and forced expiratory volume (FEV), how fast you can exhale that amount. Both of these parameters are useful for gauging the effectiveness of treatment and as clinical parameters for hospital discharge. However, spirometry relies entirely on full patient cooperation — not always a sure thing — and cannot provide a continuous, breath-by-breath measurement of airflow.

Measurement of arterial blood gases allows clinicians to gauge the degree of hypoxia and or hypercarbia present, but it is an invasive procedure with all of the associated inherent risks; such as infection, pain, and interruption of arterial flow. Also, arterial blood gases are usually normal in asthma patients who are not in acute bronchospasm, thus making it a poor clinical parameter for hospital discharge.

Using waveform capnography as an asthma assessment tool
In the prehospital environment, where EMS providers rarely have access to ABG measurement and spirometry, quantitative waveform capnography can serve as an accurate, noninvasive parameter useful in both initial assessment and in gauging the effectiveness of therapy in the asthma patient [6].

While the focus here is on asthma, these techniques are applicable to all causes of acute bronchospasm, such as COPD, bronchiectasis and cystic fibrosis.

A normal capnography waveform tracing has four discrete phases:

  • Phase I: the inspiratory baseline, typically devoid of carbon dioxide (A to B).
  • Phase II: the expiratory upstroke, a sharp incline in which CO2 levels increase dramatically (B to C).
  • Phase III: the alveolar plateau, in which CO2 concentration levels off. (C to D)
  • Phase 0: the inspiratory downstroke, the beginning of inspiration in which CO2 levels fall dramatically (D to E).

Normal waveform (Image courtesy of Kelly Grayson)

Other features include the alpha (α) angle, which is the transition from Phase II to Phase III, and the beta (β) angle, which is the transition from Phase III to Phase 0. Typically, the quantitative PetCO2 is measured at the beta angle.

In the patient with normal pulmonary pathophysiology, the alveoli empty at a fairly constant rate until full expiration of respiratory gases, resulting in a nearly-vertical Phase II, and a relatively acute alpha angle.
Normal tracing (Image courtesy of Kelly Grayson)

In the acute bronchospasm patient, however, alveoli empty at a very uneven rate, resulting in a sloped Phase II and a flattened or even indistinct alpha angle. Often, Phase II and Phase III appear to "slur" into one another.

If significant air trapping has resulted in hypercapnia, the quantitative PetCO2 measurement at the beta angle may also be higher than normal. This results in the characteristic shark fin waveform seen in acute bronchospasm.

Bronchospasm waveform (Photo courtesy of Kelly Grayson)

Normal arterial carbon dioxide (PaCO2) is 35-45 mm Hg, and studies have demonstrated strong concordance between arterial and alveolar expired carbon dioxide [7]. Even in the patient with acute bronchospasm, PetCO22 is typically within 1 mm Hg of PaCO22.

Flattening of the alpha angle and increased slope in Phase II and Phase III, while not exactly correlated with peak flow measurements obtained in spirometry, have been demonstrated to accurately reflect the degree of bronchospasm and airway narrowing in asthma patients [8, 9, 10].  Waveform capnography, while not yet a replacement for spirometry, does provide a continuous, breath-by-breath monitoring parameter independent of patient effort that spirometry does not.

By using quantitative waveform capnography as an adjunct to history and physical assessment, paying particular attention to the slope of Phase II and III, flattening of the alpha angle, and presence of hypercapnia, the EMS provider has a powerful tool to aid in assessing and treating our asthma patients.


  1. World Health Organization Fact Sheet No. 307: Asthma. May 2011.
  2. Summary Health Statistics for U.S. Children: National Health Interview Survey, 2012, table 1
  3. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2012, table 3, 4
  4. National Hospital Ambulatory Medical Care Survey: 2011 Emergency Department Summary Tables. Table 12
  5. Centers for Disease Control and Prevention, Vital Signs, May 2011.
  6. Yaron M, Padyk P, Hutsinpiller M, Cairns CB. Utility of the Expiratory Capnogram in the Assessment of Bronchospasm. Annals of Emergency Medicine. Volume 28, Issue 4, October 1996, Pages 403–407.
  7. Corbo J, Bijur P, Lahn M, Gallagher EJ. Concordance Between Capnography and Arterial Blood Gas Measurements of Carbon Dioxide in Acute Asthma. Annals of Emergency Medicine. Volume 46, Issue 4, October 2005, Pages 323–327.
  8. Howe TA, Jaalam K, Ahmad R, Sheng CK, Rahman H. The Use of End-Tidal Capnography to Monitor Non-Intubated Patients Presenting with Acute Exacerbation of Asthma in the Emergency Department. The Journal of Emergency Medicine. Volume 41, Issue 6, December 2011, Pages 581–589.
  9. N. A. R. Nik Hisamuddin, Rashidi A, Chew KS, Kamaruddin J, Idzwan Z, Teo AH. Correlations between capnographic waveforms and peak flow meter measurement in emergency department management of asthma. International Journal of Emergency Medicine. (2009) 2:83–89.
  10. You B, Peslin R, Duvivier C, Vu VD, Grilliat JP. Expiratory capnography in asthma: evaluation of various shape indices. European Respiratory Journal. 1994 Feb;7(2):318-23.

Request product info from top EMS Capnography companies

Thank You!

By submitting your information, you agree to be contacted by the selected vendor(s) and that the data you submit is exempt from Do Not Sell My Personal Information requests. View our Terms of Service and Privacy Policy.

Join the discussion

Copyright © 2021 EMS1. All rights reserved.